Timely Intervention in T2DM: Focus on SGLT2-DPP-4 Inhibitor Combinations |
Columnist
eMediNexus Coverage from: 
Timely Intervention in T2DM: Focus on SGLT2-DPP-4 Inhibitor Combinations
Dr AG Unnikrishnan, Pune,  06 June 2022
Coronavirus Live Count Map India

remove_red_eye 1700 Views
COVID-19 Vaccine Updates


#Diabetes and Endocrinology #Multispeciality

3 Read Comments                

The sequential treatment approach is often compounded by substantial clinical inertia to timely treatment intensification. Substantial clinical inertia exists at each sequential intensification step.

At HbA1c 8.0% to 8.5%, HbA1c-lowering is slightly greater with DPP-4 inhibitors than with SGLT2 inhibitors as an add-on to metformin.

SGLT2 inhibitors are associated with larger HbA1c levels.

DPP-4 inhibitors moderate the risk of genitourinary tract infections associated with SGLT2 inhibitors.

In cases of HbA1c ≥8.0%, dual DPP-4 inhibitors-SGLT2 inhibitors add-on therapy to metformin should be considered to help more patients achieve glycemic targets.

Real-world evidence with empagliflozin and linagliptin FDC conducted across India involving 1232 T2D patients showed a significant reduction in HbA1c, FPG, PPG, weight and BP.

To comment on this article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now